European Commission Must Decide If ‘Traditional Use’ Can Break Botanicals Deadlock

Allowing evidence for “traditional use” could break the regulatory deadlock regarding health claims made for botanical food supplements, the European Commission has suggested. This would unlock innovation currently stunted by the “on hold” situation, note researchers Alie de Boer and Karin Lenssen in a paper for the European Parliamentary Research Services (EPRS). However, there are regulatory issues that would need to be resolved for this to work, they point out.

It’s time to decide whether evidence of “traditional use” for botanical ingredients can be used to substantiate health claims made for food in the European Union, argues a report recently published by the European Parliament.

Otherwise, the uncertainty produced by the current regulatory situation, in which over 2,000 botanical health claims are “on hold” while...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Urban Wastewater Directive: AESGP Requests Intervention In EFPIA’s Legal Action

 
• By 

AESGP has formally submitted a request to the General Court of the European Union to intervene in the European Federation of Pharmaceutical Industries and Association’s legal action against the revised EU Urban Wastewater Directive.

Over The Counter: Seizing The Healthy Aging Opportunity, With Prime Fifty’s Max Gowland

 
• By 

HBW Insight speaks to Prime Fifty founder and managing director Max Gowland about the science behind healthy aging and the opportunity for the consumer health industry.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

German Switch Committee Supports OTC Melatonin And Acyclovir, Rejects Rupatadine

 
• By 

Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.

More from Geography

Pharma Deutschland Seeks To Enter Urban Wastewater Legal Dispute

 
• By 

The Urban Wastewater Treatment Directive “in its current form, is at an end,” insists Pharma Deutschland CEO Jörg Wieczorek. To put the directive to bed once and for all, the association has applied for leave to intervene in the ongoing EU legal battle in its own right.

Haleon Invests In State-Of-The-Art Oral Care R&D Facility In The UK

 
• By 

Haleon described the opening of a new oral care R&D facility in the UK as a “major investment reflecting our commitment to advancing science and innovation.”

Viatris Switches Innovative Dual Action Nasal Spray In The UK

 
• By 

Now available without a prescription, Dymista Control is the first OTC combination treatment for consumers who are struggling to control their seasonal allergic rhinitis with a corticosteroid or antihistamine nasal spray, according to the firm.